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Abstract- The aim of the study was to investigate the 
prevalence of metabolic syndrome in patients with 
uric acid and calcium–based kidney stones and to 
investigate the relationship between metabolic 
syndrome and type of kidney stone using infrared 
spectroscopy to evaluate the chemical composition 
of kidney stones 
Sixty patients with urolithiasis were examined. 
Metabolic syndrome was diagnosed according to 
clinical and laboratory criteria. Weight, height, 
body mass index, waist circumference, and blood 
pressure of patients were measured. Blood tests 
were performed. Concentrations of total cholesterol, 
low density lipoprotein cholesterol, high density 
lipoprotein cholesterol, triglycerides, glucose and 
uric acid in blood, were analyzed. The kidney stones 
of patients were removed and the composition of 
each kidney stone was analyzed using Fourier 
transform infrared spectroscopy.  
Metabolic syndrome was diagnosed in 55% of the 
patients; 86.7% of patients with uric acid (UA) 
kidney stones and 44.4% of patients with calcium 
(Ca) based stones had metabolic syndrome. All 
patients diagnosed with metabolic syndrome were 
overweight or obese. Even though there were no 
statistically significant differences observed 
concerning the anthropometrical measures and 
arterial blood pressure (BP) between the UA stone 
formers and Ca–based stone formers, the results 
show a trend that failed to reach significance: 
higher waist size, BMI and arterial BP means in the 
group of patients with UA stones than in the 
patients with Ca–based stones. No statistically 
significant differences in lipid profile between the 
groups were found. Concentration of UA in blood 
serum was significantly higher in patients with UA 
kidney stones than it was in patients with Ca–based 
kidney stones. Significant positive correlation 
between triglycerides and serum UA concentrations, 
as well as body mass index and serum UA 
concentration, and negative correlation between 
concentrations of high-density lipoprotein 
cholesterol and UA was found.  
Conclusion: Metabolic syndrome was more 
prevalent in patients with uric acid stones than in 
the patients with calcium–based kidney stones, even 
though this relationship was not statistically 
significant, most likely because of the limited 
number of patients investigated. 
 
Key words- kidney stone; urolithiasis; infrared 
spectroscopy; metabolic syndrome 
 
I. INTRODUCTION 
Kidney stone disease and metabolic syndrome are 
both multifactorial disorders. Over recent decades 
a big increase in the morbidity of kidney stone 
disease and metabolic syndrome was noticeable 
in developed countries including Lithuania [1–3]. 
These disorders are considered to be a public 
health problem that is highly affected by the 
process of urbanization as well as lifestyle and 
nutrition habits. Maalouf and colleagues (2007) 
were among the first to report a relationship 
between metabolic syndrome and low urine pH, 
which is related to the age and kidney function of 
the patient [4]. Previous studies have already 
demonstrated the importance of decreased urine 
pH in the formation of uric acid kidney stones due 
to its effect on uric acid solubility, crystallization, 
precipitation, adhesion and aggregation [5]. 
Nevertheless, pathophysiological mechanisms of 
urolithiasis remain unclear. Studies concerning 
this topic provide contradictory results. Cupisti et 
al. analyzed the biochemical composition of urine 
and insulin resistance of patients with kidney 
calcium stones and concluded that metabolic 
syndrome leads to decreased insulin resistance, 
which in turn suppresses citrate excretion and 
leads to the formation of calcium stones in the 
urinary tract [6]. This study, however, did not 
analyze the composition of kidney stones. Other 
researchers report a link between arterial 
hypertension, which is one of the components of 
metabolic syndrome, and disrupted calcium 
metabolism, which results in hypercalciuria and 
calcium stone formation in kidneys [7]. The 
NHANES III study (2008) also reported a 
relationship between metabolic syndrome and 
kidney stone disease, but it does not indicate what 
the composition of stones formed in patients with 
metabolic syndrome was [8]. Therefore, lack of 
information about the exact composition of stones 
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 and the nutritional habits of patients is among the 
main shortcomings of the current research on the 
topic. In recent years more publications 
concerning the composition of kidney stones have 
been published. These publications address the 
causes of kidney stone disease and its relationship 
with metabolic syndrome [1,7–12]. Nevertheless, 
the data concerning the relationship of metabolic 
syndrome and type of kidney stone remain 
contradictory. 
The aim of this study was to investigate the 
prevalence of metabolic syndrome in patients 
with uric acid and calcium–based kidney stones 
and to investigate the relationship between 
metabolic syndrome and type of kidney stone 
using infrared spectroscopy to evaluate the 
chemical composition of kidney stones. 
 
II. MATERIALS AND METHODS 
Study design 
A total of 60 men (aged 24–77, average age 
53.1±14.1) suffering from kidney stone disease 
and hospitalized at the Vilnius University 
Hospital gave their consent to participate in the 
study. All patients were thoroughly examined in 
order to diagnose metabolic syndrome according 
to clinical and laboratory criteria. The kidney 
stones of patients were removed and the chemical 
composition of the stones was examined using 
infrared spectroscopy.  
The study protocol was approved by the Vilnius 
Regional Bioethics Committee (Approval No. 
158200-5-053-056LP1). 
Anthropometric measurements 
The height, weight, and waist circumference of 
the patients were measured and the body mass 
index (BMI) was calculated. Arterial blood 
pressure (BP) was measured by a mercury 
sphygmomanometer three times while a patient 
was lying relaxed. 
Diagnosis of metabolic syndrome 
The criterion for the diagnosis of metabolic 
syndrome was selected according to American 
Heart Association (AHA) and National Heart, 
Lungs and Blood Institute (NHLBI) 
recommendations that apply ATP III (National 
Cholesterol Education Program (NCEP) Adult 
Treatment Panel III) criteria [13] with minimal 
adjustments (Table 1). 
 
TABLE 1. Clinical criterion for the metabolic 
syndrome diagnosis 
Criteria (any three criteria out of five) 
Increased waist size >102 cm (for men), and 88 
cm (for women) 
Increased triglyceride concentration ≥1.7 mmol/l 
or treatment of hypertriglyceridemia 
Decreased HDL–Ch concentration <1.03 mmol/l 
(for men), and <1.29 mmol/l (for women), or 
treatment of decreased HDL–Ch concentration 
Increased arterial BP ≥130/85 mmHg or treatment 
of hypertension 
Increased fasting glucose concentration ≥6.1 
mmol/l or treatment of increased glucose 
concentration 
 
Blood tests 
Concentrations of total cholesterol (TCh), high 
density lipoprotein cholesterol (HDL–Ch), low 
density lipoprotein cholesterol (LDL–Ch), and 
triglyceride (TG) in blood serum were measured 
by the enzymatic photometric method (Architect; 
8200 Abbott). Glucose concentration in blood 
serum was measured by hexokinase photometry, 
and uric acid (UA) concentration in blood was 
measured by uricase POD method (8200 Abbott). 
Infrared spectroscopy measurements 
Infrared absorption spectra were recorded by 
using a Vertex 70 (Bruker Optik GmbH, 
Ettlingen, Germany) FT–IR spectrometer 
equipped with globar light source, KBr 
beamsplitter, and liquid nitrogen cooled MCT 
detector. The spectra were recorded in the 4000–
500 cm
-1
 spectral range with spectral resolution of 
4 cm
-1
. For the resultant spectrum, 128 
interferograms were averaged and Fourier 
transformed into a spectrum by applying 
Blackmann–Harris 3 apodization function and 
zero filling factor 2. The stone samples were 
prepared by the KBr pellet technique [14, 15].   
Statistical analysis 
The homogeneity of frequency distributions 
between patients with different stones was 
assessed using the Pearson chi–square test for 
each metabolic syndrome component. Continuous 
variables were checked for the normality of 
distribution by the Kolmogorov-Smirnov test with 
Lilliefors Significance Correction. Continuous 
variables are expressed as mean±SD. An 
independent samples t–test was applied to 
compare the mean values of waist circumference; 
BMI; systolic and diastolic arterial BP; and 
concentration of TCh, HDL–Ch, LDL–Ch, TG, 
glucose, and UA in blood between the patients 
with calcium oxalate and uric acid. Pearson‟s 
correlation coefficient was computed while 
examining the relationship between concentration 
of UA in blood and the components of metabolic 
syndrome.  
The level of significance was set at 0.05. The 
statistical software IBM SPSS (v.21) was used for 
the statistical analysis. 
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III.   RESULTS 
Composition of kidney stones 
Fig.1 shows the prevalence of different types of 
stones removed from the patients; calcium oxalate 
(CaOx) stone with apatite being the most 
common and CaOx stone with amorphous 
calcium phosphate (ACP) being the least common 
types of kidney stone. Fig.2 shows infrared 
spectrum of CaOx stone with apatite. 
 
 
Figure 1.  Prevalence of various types of kidney stones among 
the participants (%) 
 
 
 
Figure 2. Infrared spectra of CaOx stone with apatite (a) and 
reference spectra of pure CaOx (b), and apatite (c) in the 
2000–500 cm-1 spectral range 
 
For further analysis all kidney stones were 
divided into two groups: uric acid (UA) stones 
(25%) and calcium (Ca) based stones (75%), 
which involved both CaOx stones with apatite 
and amorphous calcium phosphate (ACP). 
Metabolic syndrome and type of kidney stone 
Metabolic syndrome was diagnosed in 55% of the 
patients. 86.7% of patients with UA kidney stones 
and 44.4% of patients with Ca–based stones had a 
metabolic syndrome.  
Anthropometric data 
The results of the analysis of the anthropometric 
data are presented in Table 2.  
 
TABLE 2. Comparison of anthropometrical 
measures and arterial blood pressure among the 
metabolic syndrome patients with calcium–based 
and uric acid kidney stones. 
Index Patients with 
calcium-
based kidney 
stones 
Patients with 
uric acid 
kidney stones 
p value 
mean±SD 
 
mean±SD 
 
Waist 
size, cm 
102.32±9.87 107.5±10.88 0.108 
BMI, 
kg/m² 
27.5±3.5 28.3±3.1 0.437 
Systolic 
BP, 
mmHg 
136.6±10.03 141.43±9.49 0.124 
Diastolic 
BP, 
mmHg 
84.88±5.94 87.86±5.48 0.105 
 
All patients diagnosed with metabolic syndrome 
were overweight or obese. Even though there 
were no statistically significant differences 
observed concerning the anthropometric 
measurements and arterial BP between the two 
groups of patients, the results show a trend that 
failed to reach significance: higher waist size, 
BMI and arterial BP means in the group of 
patients with UA stones than in the patients with 
Ca–based stones.   
Results of blood tests 
The results of blood tests are summarized in 
Table 3. No statistically significant differences in 
lipid profile between the groups of patients with 
UA and Ca–based stones were found. Of note, 
mean lipid and lipoprotein concentration in blood 
did not exceed normal ranges, except for TG 
concentration, which was higher in the blood of 
patients with UA kidney stones. Glucose 
concentration in blood serum was higher than 
recommended, in particular in patients with UA 
kidney stones. 
Concentration of UA in blood serum was 
significantly higher in patients with UA kidney 
stones than it was in patients with Ca–based 
kidney stones (444.5±109.6 µmol/l vs. 345.8±91 
µmol/l, p=0.016). For the determination of the 
relationship between the concentration of UA in 
blood serum and the components of metabolic 
syndrome the Pearson correlation coefficient was 
calculated (r). The results are presented in Table 
4. 
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 TABLE 3. Comparison of blood biochemical 
indices among the metabolic syndrome patients 
with calcium–based and uric acid kidney stones 
  Patients with 
calcium-
based kidney 
stones 
Patients 
with uric 
acid kidney 
stones 
p value 
mean± SD 
 
mean± SD 
 
TCh, 
mmol/l 
5.08±0.93 4.63±0.80 0.103 
HDL–Ch, 
mmol/l 
0.97±0.19 0.86±0.18 0.057 
LDL–Ch, 
mmol/l 
3.39±0.84 2.93±0.74 0.065 
TG, 
mmol/l 
1.55±0.53 1.79±0.59 0.134 
Glucose, 
mmol/l 
5.99±1.46 6.28±1.53 0.519 
UA, 
μmol/l 
345.8±91 444.5±109.6 0.016* 
*p<0.05 
 
 
TABLE 4. Correlation between components of 
metabolic syndrome and uric acid concentration 
in blood serum in uric acid stone formers. 
Index 
Uric acid concentration 
in blood (µmol/l) (r) 
BMI, kg/m2 0.373* 
Waist size, cm 0.342 
Systolic BP, mmHg 0.009 
Diastolic BP, mmHg 0.173 
TCh, mmol/l 0.004 
LDL–Ch, mmol/l -0.041 
HDL–Ch, mmol/l  -0.421* 
TG, mmol/l 0.423* 
Glucose, mmol/l -0.184 
*p<0.05 
 
Components of metabolic syndrome 
The percentage frequency of the separate 
components of metabolic syndrome among 
patients with pure UA and Ca–based kidney 
stones are presented in Table 5. No significant 
differences between the patients with different 
stones were observed. 
TABLE 5. Frequency of components of metabolic 
syndrome among patients with uric acid and 
calcium–based kidney stones 
Component of 
metabolic 
syndrome 
Patients with 
calcium-based 
kidney stones 
Patients with 
uric acid kidney 
stones 
n % 
 
n % 
 
BMI, (≥25 
kg/m
2
) 
28 62.2 12 80 
Increased TG 
concentration, 
(>1.7 mmol/l) 
16 35.6 7 46.7 
Decreased 
HDL–Ch 
concentration, 
(<1.03 mmol/l) 
28 62.2 12 80 
Hyperglicemia, 
(>6.1 mmol/l) 
17 37.8 6 40 
Increased 
systolic BP 
(>130 mmHg) 
24 53.3 11 73.3 
Increased 
diastolic BS 
(>85 mmHg) 
21 46.7 9 60 
 
IV.   DISCUSSION 
The study demonstrated that CaOx kidney stones 
are the most common type of stones removed 
from patients with kidney stone disease. This 
result is in accordance with previous studies, 
which have reported that CaOx and mixed 
calcium stones are the most common type of 
kidney stone, comprising 78–80% of all stones 
removed from patients with kidney stone disease 
in the developed countries [16–18]. UA stones are 
less common and comprise only 5 to 10% of all 
kidney stones [19–20]. 
Positive correlation between BMI and uric acid 
concentration in blood serum, which is involved 
in the pathogenesis of uronephrolithiasis, is 
compatible with other studies that have proved a 
connection between higher BMI and the 
formation of UA kidney stones [21–24]. Daudon 
and colleagues have reported that overweight and 
obese people develop calcium stones much less 
often than people with normal BMI, and the rate 
of UA stone formation increases with an increase 
in BMI [25]. Other findings, however, have 
indicated a link between obesity and increased 
risk of the formation of Ca–based kidney stones 
[17, 24]. In the present study, the concentration of 
UA in serum was significantly higher in patients 
with UA urolithiasis. Examination of UA 
concentration in blood serum revealed a 
significant positive medium correlation between 
TG concentration and concentration of UA as 
well as BMI and concentration of UA. There was 
a significant negative medium correlation 
between HDL–Ch and concentration of UA in 
blood serum. The results of this study are in 
accordance with other studies [26, 27]. Pacifico 
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 has revealed significant relationships between the 
concentration of serum UA and BMI, systolic BP, 
and the concentration of HDL–Ch and TG [28]. 
Meanwhile, Kawamoto [29] has reported a 
significant relationship between the concentration 
of serum UA and TG, BMI, and low HDL–Ch. 
Hyperuricosuria and metabolic acidosis decreases 
urine pH and leads to the formation of UA kidney 
stones [20, 30].  
Elevated arterial BP is one of the components of 
metabolic syndrome. It is believed that there is a 
link between the formation of kidney stones and 
high arterial BP. It has been demonstrated that 
patients suffering from kidney stones are at higher 
risk of developing arterial hypertension; 
meanwhile, patients with primary arterial 
hypertension more often develop kidney stone 
disorder [7, 22, 30]. Data of research examining 
which type of stones is common among patients 
suffering from arterial hypertension are 
contradictory. Some researchers link arterial 
hypertension with the formation of UA stones, 
whereas others report a connection between 
arterial hypertension and the formation of calcium 
stones [7, 31]. The present study, however, did 
not confirm a significant relationship between the 
type of kidney stone and arterial hypertension. 
According to some researchers, insulin resistance 
and hyperglycemia cause formation of UA stones 
[4]. Meanwhile, other authors have reported a 
relationship between insulin resistance, 
hyperglycemia, and the formation of Ca–based 
kidney stones [6]. No significant relationship 
between glucose levels and the type of kidney 
stone was observed in the present study, however. 
The results of recent investigations have shown 
that patients suffering from metabolic syndrome 
have a significant higher prevalence of kidney 
stone disease and its prevalence increases with the 
increase in the number of metabolic syndrome 
components [22]. Nevertheless, few studies have 
been conducted examining the relationship 
between metabolic syndrome and the chemical 
composition of kidney stones [31]. The results of 
present study do not confirm statistically 
significant relationship between any particular 
component of metabolic syndrome and the type of 
kidney stone. Metabolic syndrome however was 
diagnosed more frequently in patients with uric 
acid stones than those with Ca–based stones. The 
main limitation of this study was the small 
number of the patients investigated.  
V.   CONCLUSION 
Metabolic syndrome was more prevalent in 
patients with uric acid stones compared to the 
patients with calcium-based kidney stones even 
though this relationship was not statistically 
significant, most likely because of the limited 
number of patients investigated. This is a 
significant area of interest that requires further 
studies. 
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